Rhumbline Advisers Mannkind Corp Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Mannkind Corp stock. As of the latest transaction made, Rhumbline Advisers holds 382,226 shares of MNKD stock, worth $2.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

382,226

Previous 382,803 0.15%

Holding current value

$2.14 Million

Previous $2.4 Million 2.2%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	SELL	$5.93 - $7.44 $3,421 - $4,292	-577 Reduced 0.15%	382,226 $2.46 Million
Q3 2024 Nov 12, 2024	SELL	$5.01 - $6.7 $72,098 - $96,419	-14,391 Reduced 3.62%	382,803 $2.4 Million
Q2 2024 Aug 01, 2024	BUY	$4.05 - $5.43 $79,683 - $106,835	19,675 Added 5.21%	397,194 $2.07 Million
Q1 2024 May 09, 2024	BUY	$3.25 - $5.27 $25,762 - $41,775	7,927 Added 2.14%	377,519 $1.71 Million
Q4 2023 Feb 08, 2024	SELL	$3.34 - $4.29 $40,667 - $52,235	-12,176 Reduced 3.19%	369,592 $1.35 Million
Q3 2023 Nov 09, 2023	BUY	$3.91 - $5.45 $22,036 - $30,716	5,636 Added 1.5%	381,768 $1.58 Million
Q2 2023 Aug 08, 2023	SELL	$3.72 - $4.79 $133,164 - $171,467	-35,797 Reduced 8.69%	376,132 $1.53 Million
Q1 2023 May 11, 2023	BUY	$3.95 - $5.63 $64,116 - $91,386	16,232 Added 4.1%	411,929 $1.69 Million
Q4 2022 Feb 14, 2023	BUY	$3.02 - $5.37 $29,139 - $51,815	9,649 Added 2.5%	395,697 $2.09 Million
Q3 2022 Nov 10, 2022	BUY	$2.99 - $4.35 $71,362 - $103,821	23,867 Added 6.59%	386,048 $1.19 Million
Q2 2022 Aug 11, 2022	BUY	$2.67 - $4.77 $124,189 - $221,867	46,513 Added 14.73%	362,181 $1.38 Million
Q1 2022 May 12, 2022	SELL	$2.62 - $4.45 $54,582 - $92,706	-20,833 Reduced 6.19%	315,668 $1.16 Million
Q4 2021 Feb 10, 2022	SELL	$4.05 - $5.37 $12,044 - $15,970	-2,974 Reduced 0.88%	336,501 $1.47 Million
Q3 2021 Nov 12, 2021	BUY	$3.89 - $5.48 $41,109 - $57,912	10,568 Added 3.21%	339,475 $1.48 Million
Q2 2021 Aug 05, 2021	BUY	$3.61 - $5.45 $348,837 - $526,638	96,631 Added 41.6%	328,907 $1.79 Million
Q1 2021 May 06, 2021	SELL	$3.14 - $6.14 $40,663 - $79,513	-12,950 Reduced 5.28%	232,276 $911,000
Q4 2020 Feb 10, 2021	BUY	$1.79 - $4.04 $31,128 - $70,255	17,390 Added 7.63%	245,226 $768,000
Q3 2020 Nov 12, 2020	SELL	$1.56 - $2.08 $57,135 - $76,180	-36,625 Reduced 13.85%	227,836 $428,000
Q2 2020 Aug 13, 2020	BUY	$0.94 - $2.21 $26,774 - $62,947	28,483 Added 12.07%	264,461 $463,000
Q4 2019 Feb 05, 2020	BUY	$1.14 - $1.49 $1,868 - $2,442	1,639 Added 0.7%	235,978 $304,000
Q3 2019 Oct 23, 2019	SELL	$1.04 - $1.44 $1,612 - $2,232	-1,550 Reduced 0.66%	234,339 $293,000
Q2 2019 Aug 14, 2019	BUY	$1.09 - $1.88 $37,103 - $63,995	34,040 Added 16.86%	235,889 $271,000
Q1 2019 May 01, 2019	BUY	$1.14 - $2.25 $21,783 - $42,993	19,108 Added 10.46%	201,849 $398,000
Q4 2018 Jan 31, 2019	BUY	$1.02 - $2.05 $61,825 - $124,256	60,613 Added 49.63%	182,741 $194,000
Q3 2018 Nov 07, 2018	SELL	$1.01 - $2.19 $9,216 - $19,983	-9,125 Reduced 6.95%	122,128 $223,000
Q2 2018 Aug 06, 2018	BUY	$1.59 - $2.38 $208,692 - $312,382	131,253 New	131,253 $249,000

Others Institutions Holding MNKD

# of Institutions

248

Shares Held

148M

Call Options Held

1.62M

Put Options Held

802K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.44B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Mannkind Corp Transaction History